Alyeska Investment Group
ACAD icon

Alyeska Investment Group’s Acadia Pharmaceuticals ACAD Stock Holding History

Alyeska Investment Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.85M Buy
+310,287
New +$6.83M 0.02% 458
2024
Q2 		– Sell
-85,696
Closed -$1.58M – 558
2024
Q1 		$1.58M Sell
85,696
-499,340
-85% -$12.4M 0.01% 391
2023
Q4 		$18.3M Buy
585,036
+185,036
+46% +$4.42M 0.12% 213
2023
Q3 		$8.34M Buy
+400,000
New +$10.9M 0.06% 305
2019
Q1 		– Sell
-175,000
Closed -$2.83M – 368
2018
Q4 		$2.83M Buy
+175,000
New +$3.4M 0.04% 267
2018
Q2 		– Sell
-614,166
Closed -$13.8M – 447
2018
Q1 		$13.8M Sell
614,166
-41,336
-6% -$1.14M 0.11% 196
2017
Q4 		$19.7M Buy
655,502
+289,583
+79% +$9.26M 0.16% 157
2017
Q3 		$13.8M Sell
365,919
-80,511
-18% -$2.62M 0.1% 215
2017
Q2 		$12.5M Buy
446,430
+73,593
+20% +$2.19M 0.1% 221
2017
Q1 		$12.8M Buy
+372,837
New +$13.2M 0.1% 236

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Alyeska Investment Group's ACAD Position: Q2 2026 in Review

Alyeska Investment Group opened a new position in Acadia Pharmaceuticals (ACAD) in Q2 2026: 310,287 shares worth $7.85M. The stake represents 0.02% of the portfolio and ranks #458 among its holdings. This is a return to the name: Alyeska Investment Group previously reported a position in ACAD as recently as Q1 2024.

Alyeska Investment Group first reported a position in ACAD in Q1 2017 and has held it in 10 quarters since. The position peaked at $19.7M in Q4 2017. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Alyeska Investment Group held 310,287 shares of Acadia Pharmaceuticals worth $7.85M as of Q2 2026.
  • Acadia Pharmaceuticals was a new Alyeska Investment Group position in Q2 2026.
  • Acadia Pharmaceuticals made up 0.02% of Alyeska Investment Group's portfolio in Q2 2026, its #458 holding.
  • Alyeska Investment Group first reported a position in Acadia Pharmaceuticals in Q1 2017 and has held it in 10 quarters since.
  • Alyeska Investment Group's Acadia Pharmaceuticals position peaked at $19.7M in Q4 2017.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Alyeska Investment Group's 13F filing for Q2 2026, filed 14 Aug 2026.